Karyopherin-α2 (KPNA2) functions as an adaptor that transports several proteins to the nucleus. We investigated the clinical and functional significance of KPNA2 in gastric cancer (GC). Immunohistochemistry was performed to examine KPNA2 expression in primary GC and metastatic lymph nodes. Next, KPNA2 was suppressed by small interfering RNA (siRNA) to examine KPNA2 function in proliferation and cisplatin-induced apoptosis of GC cell lines. Nuclear expression of KPNA2 in marginal regions of primary GC was stronger than in central regions of GC and normal tissues. The high expression of marginal KPNA2 was significantly associated with β-catenin accumulation in the nucleus and poor prognosis in two independent GC cohorts (discovery cohort, n = 90, P = 0.018; validation cohort, n = 89, P = 0.0125). We detected correlations between nuclear KPNA2 expression in marginal region and progression of macroscopic type (P = 0.036), tumor depth (P = 0.013), lymph node metastasis (P = 0.0064), venous invasion (P = 0.034) and clinical stage (P = 0.0006). Nuclear KPNA2 expression in marginal regions of metastatic lymph nodes was significantly higher than in the central region. It was associated with poor survival of GC patients with lymph node metastasis (n = 96; center, P = 0.4384; marginal, P < 0.0001). KPNA2 suppression enhanced cisplatininduced apoptosis and reduced proliferation in the KPNA2 siRNA group compared with the control siRNA group. The expression of the DNA repair gene NBS1 (NBN) in the nucleus was suppressed in KPNA2-suppressed cells. KPNA2 might be a useful prognostic marker and an effective therapeutic target for GC.
Introduction
Gastric cancer (GC) is now one of the most common malignancies worldwide (1, 2) . Despite the development and identification of novel anticancer agents and treatment methods, GC is still an aggressive malignancy. In patients with recurrent or refractory GC, the prognosis is poor (3) . To prevent recurrence after curative resection and treatment with anticancer agents, cancer therapies must be improved.
In this study, we focused on karyopherin-α2 (KPNA2). We were the first to report the high expression level of the KPNA2 gene in GC compared with normal gastric mucosa using re-analysis of a GEO database. KPNA2 is thus recognized as a GC-specific gene (4, 5) . KPNA2 is a member of the importin family. It consists of an IBB domain, eight armadillo repeats that are involved in recognition and binding to nuclear localization signals and a C-terminal acidic domain (6) . Importin-α is a major component of nuclear pore complexes required for transporting various macromolecules larger than 50 KDa or other complex proteins (7, 8) . The nuclear transport signaling pathway was previously identified as important for tumorigenesis and tumor development in several cancers (8) .
Recent studies have reported that KPNA2 functions as a novel oncogenic factor in human breast cancer and in non-small cell lung cancer (9, 10) . Moreover, high expression of KPNA2 was associated with poor prognosis and cancer progression in non-muscle-invasive bladder cancer (11) , epithelial ovarian cancer (12) and esophageal squamous cell carcinoma (13) . In comparison, the expression levels of KPNA2 were reported to be very low in various normal tissues (14, 15) . These reports suggest that KPNA2 represents a new therapeutic target and a useful biomarker to predict malignant potential. However, there is still inadequate information regarding KPNA2 expression and clinicopathological significance in GC.
The purpose of this study was to clarify KPNA2 function in GC cell lines in vitro. We also examined the clinical significance of KPNA2 in primary GC and metastatic lymph nodes. Therefore, immunohistochemistry was performed to evaluate the relationships between KPNA2 expression and clinicopathological significance in clinical GC samples. Finally, we examined the in vitro effects of small interfering RNA (siRNA)-mediated KPNA2 suppression on proliferation potency and cisplatin-induced apoptosis in human GC cell lines.
Materials and methods

Clinical samples and cell lines
We used restricted primary GC tissues and pathological metastatic lymph nodes from 179 GC patients (127 males and 52 females) who underwent potentially curative surgery at Department of General Surgical Science, Gunma University Hospital, between 1996 and 2006. All clinical GC samples in this study were used in accordance with institutional guidelines and the Helsinki Declaration after obtaining written informed consent from all participants. First, we randomly selected 90 patients from the 352 patients treated between January 1996 and August 2000. This group was regarded as the discovery cohort. Second, we randomly selected 90 patients from the 497 patients treated between September 2000 and December 2006. (One of the samples was lost.) This group was regarded as the validation cohort. Finally, we summed the two cohorts, which were regarded as the total cohort. In the total cohort, there were 158 primary GC samples in which the tumor depth was between submucosa (SM) and serosa infiltrating. With those samples, we examined the distribution of KPNA2-high-expressing GC cells. This strategy was used because it was difficult to evaluate the distribution of mucosal cancer cells in the center and marginal regions. On the slide, the center of the tumor was defined as the central region and the invasive front was defined as the marginal region. The median follow-up period was 45 months (range, 1-93 months). The clinicopathological findings were based on the surgical records and pathology reports, and determined according to the Japanese Classification of Gastric Carcinoma outlined by the Japanese Gastric Cancer Association (16) . The age of the patients ranged from 36 to 85 years with a mean of 64.2 ± 11.2 years. Differentiated type (well and moderate differentiated) included 101 (56%) patients, and undifferentiated type (poorly differentiated and signet ring cells) included 78 (44%) patients. Tumor depth was classified into two categories: early GC (including mucosa and SM), 39 (22%) patients, and advanced GC (including muscularis propria, subserosa, serosa exposed and serosa infiltrating), 140 (78%) patients. Macroscopic type was classified in two categories: localized type (including types 0, 1 and 2), 96 (54%) patients, and infiltrated type (including types 3, 4 and 5), 83 (46%) patients. Lymphatic and vascular invasion were divided into absent 43 (24%) patients and 94 (53%) patients, respectively, and positive 136 (76%) patients and 85 (47%) patients, respectively. Stages I, II, III and IV were 76 (43%), 36 (20%), 47 (26%) and 20 (11%) patients, respectively. Eleven resected adenoma samples were collected and analyzed to evaluate KPNA2 expression by immunohistochemistry as were GC samples.
Human GC cell lines KATO-III, MKN7, MKN45 and MKN74 were maintained in RPMI 1640 containing 10% fetal bovine serum and supplemented with 100 units/ml penicillin and streptomycin sulfate, and cultured in a humidified 5% CO 2 incubator at 37°C.
Immunohistochemistry
The resected surgical specimens were fixed with 10% formaldehyde, embedded in paraffin blocks, cut into 4 μm thick sections and mounted Abbreviations: GC, gastric cancer; KPNA2, karyopherin-α2; siRNA, small interfering RNA; SM, submucosa. Figure 1F (×20 magnification). (I) Cancer-specific survival curves of GC patients according to their nuclear KPNA2 expression scores. The survival rate of the high-nuclear KPNA2-expression group was significantly lower than that of the low-expression group in two independent GC cohorts (discovery cohort, n = 90, P = 0.018; validation cohort, n = 89, P = 0.0125). (J) Left panel: mean value of nuclear KPNA2 expression level in central region and marginal region of primary GC (P < 0.0001). Middle and right panels: cancer-specific survival frequencies of 158 patients (tumor depth > SM) according to the nuclear KPNA2 expression levels in the central region (P = 0.0867) and the marginal region (P = 0.0001), respectively. (K) Cancer-specific survival curves of GC patients with lymph node metastasis according to their nuclear KPNA2 expression scores (P = 0.0016). Cancer-specific survival curves of GC patients without lymph node metastasis according to their nuclear KPNA2 expression scores (P = 0.5809). (L) The relationships between nuclear KPNA2 expression in primary lesions and in metastatic lymph nodes of patients with pathological lymph node metastasis.
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on glass slides. The staining procedure was performed by standard streptavidin-biotin peroxidase complex methods. All sections were incubated at 60°C for 60 min and deparaffinized in xylene, rehydrated and incubated with fresh 0.3% hydrogen peroxide in 100% methanol for 30 min at room temperature to block endogenous peroxidase activity. After rehydration through a graded series of the ethanol treatments, antigen retrieval was carried out in 10 mM citrate buffer (pH 6.4) at 98-100°C for 20 min, and then sections were passively cooled to 30°C. After rinsing the section in 0.1 M phosphate-buffered saline (pH 7.4), non-specific binding sites were blocked by incubation with 10% normal rabbit or goat serum for 30 min. The sections were then incubated with goat anti-KPNA2 polyclonal antibody (Santa Cruz Biotechnology), rabbit anti-β-catenin (6B3) monoclonal antibody (Cell Signaling Technology) and rabbit anti-Ki67 (Clone SP6) monoclonal antibody (Thermo Scientific) at a dilution of 1:200 in phosphate-buffered saline containing 1% bovine serum albumin overnight at 4°C and at room temperature for 30 min. The sections were washed in phosphate-buffered saline, incubated with biotinylated anti-mouse IgG, A and M solution (Nichirei Co., Tokyo, Japan) for 30 min at room temperature and finally incubated in a streptavidin-biotin peroxidase complex solution (Nichirei Co.) for 30 min. Chromogen, 3,3-diaminobenzidine tetrahydrochloride, was applied as a 0.02% solution containing 0.005% hydrogen peroxide in a 50 mM ammonium acetate-citrate acid buffer (pH 6.0). The sections were lightly counterstained in Mayer's hematoxylin and mounted. It was reported that esophageal squamous cell carcinomas expressed high levels of KPNA2 (13) . Thus, we conducted KPNA2 immunostaining procedures on four esophageal squamous cell carcinoma samples as positive controls and negative controls with the methods described in this study.
Evaluation of immunostaining
Immunohistochemical slides were scanned and evaluated by two experienced researchers; the inter-observed κ value was 0.839. The intensity of nuclear KPNA2 and β-catenin stains was scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining and 3+, strong staining. The percentage of nuclear stained cells was calculated by examining at least 2000 cancer cells in 10 representative areas. The nuclear KPNA2 and nuclear β-catenin staining percentages were scored as follows: 0, no staining; 1+, ~1-10%; 2+, ~11-50% and 3+, ~51-100%. The score was defined as the percentage score multiplied by the intensity score (0, 1+, 2+, 3+, 4+, 6+ and 9+). The optimal cut-off point for predicting CG patients' survival time according to the KPNA2 expression was defined as the high (4+, 6+ and 9+) or the low (0, 1+, 2+ and 3+) expression group in the discovery cohort. Clinical significance of the cut-off value was validated in the validation cohort. The percentage of Ki-67-stained cells was calculated by examining at least 2000 cancer cells in 10 representative areas (×200), where 1+ (<2%), 2+ (~3-20%) and 3+ (>20%). They were then classified into low (1+ and 2+) or high (3+) expression groups.
KPNA2 RNA interference KPNA2-specific siRNAs (silencer™ pre-designed siRNA 1: CAGAUACCUG CUGGGCUAUUUCCUA and siRNA 2: ACCUGCUGGGCUAUUUCCUAC CUUA) and a scrambled siRNA as a negative control (siTrio negative control 1) were purchased from Invitrogen and Hokkaido System Science, respectively. MKN7 and the MKN45 cell lines were seeded at 1 × 10 5 cells per well in a volume of 2 ml in six-well flat bottom plates and incubated in a humidified atmosphere (37°C and 5% CO 2 ). After 24 h of incubation, 500 μl Opti-MEM I reduced-serum medium liquid (Invitrogen), 5 μl lipofectamine RNAiMAX and siRNA (scrambled siRNA or KPNA2 siRNAs) were mixed and incubated for 20 min. Then, the reagents were added to each well. The RNA interference assay was performed after 24 h of incubation.
Protein extraction and western blot analysis
Western blotting was used to confirm the expression of KPNA2 and β-actin proteins in GC cell lines. Total proteins were extracted from KATO-III, MKN7, MKN45 and MKN74 with PROPREP™ protein extraction solution (iNtRON Biotechnology). Total protein was electrophoresed through Nu polyacrylamide gel electrophoresis 4-12% Bis-Tris gels (Invitrogen) and then electrotransferred to polyvinylidene difluoride membranes using an iBlot Gel Transfer Device. The membrane was blocked with 5% skim milk and the proteins were detected using anti-KPNA2 goat polyclonal antibody (1:1000) and anti-NBS1 rabbit monoclonal antibody (1:1000; Cell Signaling Technology); anti-β-actin mouse monoclonal antibody (clone AC-74; Sigma) diluted 1:1000 served as a control. Bands and band intensity were detected and calculated using ECL Prime Western Blotting Detection Reagent and Image Quant LAS 4000. 
Clinical significance of KPNA2 in gastric cancer
Cell proliferation assay Cell proliferation analysis was performed on MKN7 and MKN45 cells, both the transfected negative control and KPNA2 siRNA-treated cells. These cells were cultured in 96-well microtiter plates in 100 μl of medium containing 10% fetal bovine serum at 3 × 10 3 cells per well. After initial cell seeding, the cell viability was analyzed using a Cell Counting Kit-8 (Dojindo Laboratories, Tokyo, Japan). Ten microliters of the cell counting solution was added to each well after 0, 24, 48, 72, 96 and 120 h and incubated at 37°C in a humidified 5% CO 2 atmosphere for 2 h. The cell proliferation rates were determined at 450 nm using an Emax-precision microtiter plate reader (Molecular Devices, Sunnyvale, CA). All results were derived from six sets of duplicated experiments.
Apoptosis assay MKN7 cells transfected with KPNA2 siRNA were dispensed into 96-well plates. Twenty-four hours after the initial seeding, cisplatin was added for 48 h (cisplatin: final concentrations, 0, 1.0, 10, 100 and 1000 μM), and then cisplatin-induced apoptosis was evaluated using the fluorometric ApoOne Homogeneous Caspase-3/7 Assay (Promega Corporation, Madison, WI). All samples were performed in duplicate.
Statistical analysis
Statistically significant differences were analyzed with Student's t-test for continuous variables and the chi-square test for categorical variables. Survival curves were generated according to the Kaplan-Meier method. The differences between survival curves were examined using the log-rank test. In addition, univariate and multivariate survival analyses were performed using Cox's proportional hazards model. Analysis of variance was used to assess the statistical significance of in vitro assays. Results were considered statistically significant when the relevant P value was <0.05. All statistical analyses were performed using JMP 5.0 software (SAS Institute, Cary, NC).
Results
Nuclear KPNA2 protein expression in primary GC
The expression levels of KPNA2 protein in the nucleus were higher than those in the cytoplasm and were higher in GC tissues than in the normal gastric gland ( Figure 1A ). High expression of nuclear KPNA2 was observed in 0% (0/179) of normal gastric mucosa, 36.4% (4/11) of adenomas, 28.2% (11/39) in early GC and 50.7% (71/140) of advanced GC (Figure 1B-E; Supplementary Table 1 , available at Carcinogenesis Online). The expression levels of nuclear KPNA2 were stronger in marginal regions than in central regions ( Figure 1F-H) . Esophageal squamous cell carcinoma samples were stained with KPNA2 antibody as positive and negative control sections (Supplementary Figure A and B, available at Carcinogenesis Online).
Clinicopathologic significance of nuclear KPNA2 expression in primary GC
The high expression levels of nuclear KPNA2 in 179 GC tissues were significantly associated with progression of macroscopic type (P = 0.036), tumor depth (P = 0.013), lymph node metastasis (P = 0.0064), venous invasion (P = 0.034) and clinical stage (P = 0.0008; Table I ).
Overall survival in the nuclear KPNA2-high-expression group (n = 49) of the discovery cohort (n = 90) was significantly shorter than that of the low-expression group (n = 41, P = 0.018). With the validation cohort, the overall survival in the KPNA2-highexpression group (n = 33) was significantly shorter than that of the low-expression group (n = 56, P = 0.0125; Figure 1I ). The same results were observed in the total cohort (n = 179, P = 0.0001; Figure 1I ). The multivariate regression analysis revealed that high expression of nuclear KPNA2 in 179 GC samples was an independent prognostic factor (P = 0.023) as were tumor depth (P = 0.045), lymph node metastasis (P = 0.0013) and venous invasion (P = 0.031; Table II) .
Prognostic value of nuclear KPNA2 was stronger in the marginal region than in the central region
In the 158 invasive primary GC samples (SM ≤ tumor depth), the frequency of patients who were positive for nuclear KPNA2 was significantly higher in the marginal regions than in the central (E and F) Cancer-specific survival rates of 96 patients with pathological metastatic lymph node metastasis according to the nuclear KPNA2 expression levels in the central (P = 0.4384) and marginal (P = 0.0001) regions of metastatic lymph node sections, respectively. region (P < 0.0001; Figure 1J ). We determined the relationship between the overall survival rates of the 158 invasive primary GC patients and nuclear KPNA2 expression in the marginal and central regions. Patients with high nuclear KPNA2 in marginal regions had a significantly poorer prognosis than those with low nuclear KPNA2 (P = 0.0001). In contrast, the expression of nuclear KPNA2 in the central region was not associated with poor prognosis ( Figure 1J ).
Nuclear KPNA2 expression in 96 GC tissues with lymph node metastasis and in metastatic lymph nodes
Among the 179 GC patients, pathological metastatic lymph nodes were diagnosed in 96 patients. The expression levels of nuclear KPNA2 in the primary lesions of those 96 patients were higher than in the primary lesions of 83 patients lacking metastatic lymph nodes. The survival rate of the group with high expression of nuclear KPNA2 in the primary lesions with lymph node metastasis (n = 96) was significantly higher than those of the low-expression group (P = 0.0016; Figure 1K ). In that same group of 96 patients, 33 of 43 (77%) patients, who showed low expression of nuclear KPNA2 in the primary lesion, had high expression of KPNA2 in the metastatic lymph nodes ( Figure 1L ).
Nuclear KPNA2 expression in metastatic lymph nodes of GC As observed in primary GC tissues, the nuclear expression levels of KPNA2 in the metastatic lymph nodes were stronger in marginal regions than in central regions (Figure 2A-C) . The frequency of KPNA2-positive nuclei in the 96 formalin-fixed paraffin-embedded sections of metastatic lymph nodes was significantly higher in marginal regions than in central regions (P < 0.0001; Figure 2D ). Next, we examined the relationships between overall survival rates and nuclear KPNA2 expression in the marginal and central region of metastatic lymph nodes. As was the case with primary GC data, patients with high nuclear expression of KPNA2 in marginal regions of metastatic lymph nodes had a significantly poorer prognosis than those with low nuclear expression of KPNA2 (P < 0.0001; Figure 2F ), and the expression of nuclear KPNA2 in central regions was not associated with poor prognosis ( Figure 2E ).
Relationships between nuclear KPNA2 expression and accumulation of nuclear β-catenin and Ki-67 expression
Among the 179 GC samples immunostained with KPNA2 antibody, we were able to obtain several serial sections from 54 GC patients. Therefore, we examined the relationships between nuclear β-catenin, Ki-67 and nuclear KPNA2. High expression of KPNA2 in the serial sections was observed in 44% (24/54) of the patients. We found that accumulation of nuclear β-catenin [91.6% (22/24)] and expression of Ki-67 [70.8% (17/24)] in the region of high nuclear KPNA2 staining were both greater than in low expression regions (P < 0.0001 and P = 0.0125; Figure 3A-C) . Importantly, the expression of β-catenin in the low KPNA2 sections was restricted to the cytoplasm.
KPNA2 regulates proliferation potency and cisplatin-induced apoptosis in GC cell lines
We evaluated KPNA2 expression levels in KATO-III, MKN7, MKN45 and MKN74 cell lines by western blot ( Figure 4A ). KPNA2 expression was detected in all GC cell lines. Therefore, we used MKN7 and MKN45 to analyze the effects of KPNA2 suppression in GC cell lines in vitro.
We transfected KPNA2 siRNAs into MKN7 and MKN45 for up to 192 h to strongly knockdown KPNA2 protein. KPNA2 expression was suppressed in MKN7 and MKN45 cells treated with KPNA2 siRNA1 and siRNA2 ( Figure 4B ). The proliferation potency in groups treated with KPNA2 siRNA was significantly suppressed ( Figure 4C ).
NBS1 is a component of the MRE11-RAD50-NBS1 complex, a central player associated with repair of double-strand breaks. The expression of NBS1 in the nucleus was suppressed in the KPNA2 siRNA group compared with the control siRNA group ( Figure 4D ). After knocking down KPNA2 for a second 96 h, we measured caspase-3 and caspase-7 activities to evaluate apoptosis induction in KPNA2-suppressed groups that had been treated with cisplatin (0, 1, 10, 100 and 1000 μM). As a result, the caspase activity in KPNA2-suppressed groups was apparently higher than that in the parent and the control cells ( Figure 4E ).
Discussion
In this study, we showed that the high expression of KPNA2 in primary GC samples was associated with cancer progression and poor prognosis. Patients with high KPNA2 expression in marginal regions of primary GC and metastatic lymph nodes had poorer prognosis than low-expression groups. In our in vitro KPNA2 suppression analysis, significant cisplatin-induced apoptosis and reduced proliferation were observed in the KPNA2 siRNA treatment groups compared with the other groups.
Macromolecules larger than about 50 KDa or complex proteins, including cancer-related proteins, usually require multiple pathways to deliver them into the nucleus (7). The KPNA2 nuclear import pathway is frequently activated in various cancers and is associated with tumorigenesis and cancer progression (9) (10) (11) (12) 17) . Moreover, KPNA2 is more highly expressed in various cancers than in normal tissues, and high expression of KPNA2 has previously been confirmed as a predictor of poor prognosis in different cancers (10, 12, 13, 18, 19) . KPNA2 transports the cancer progression-related gene product NBS1 into the nucleus. NBS1 was reported to be associated with poor prognosis and the epithelial-mesenchymal transition via Snail induction in head and neck cancer (17, 20, 21) . Snail, downstream from transforming growth factor-β, reportedly induces epithelial-mesenchymal transition through E-cadherin repression and nuclear β-catenin accumulation in several cancers (22) . These reports suggested that KPNA2 might be associated with Wnt/β-catenin signaling. Therefore, we examined the correlation of KPNA2, Ki-67 and β-catenin in clinical GC samples. We found that nuclear β-catenin and Ki-67 were significantly coexpressed in clinical GC samples expressing KPNA2. Wnt/β-catenin activation in GC has been found in about 30% of patients and is related to GC progression (23, 24) . From these data, it was suggested that KPNA2 was at least partially responsible for inducing nuclear β-catenin accumulation and Wnt/β-catenin signaling activation in GC via the KPNA2/NBS1/Snail axis. Wnt/β-catenin signaling regulated by KPNA2 might be one of the causes of GC progression.
KPNA2 expression was stronger in marginal regions of primary GC and metastatic lymph nodes. Few studies have analyzed the mechanism of KPNA2 regulation in GC. In normal, transformed and cervical cancer cells, the E2F/Dp1 heterodimer upregulates KPNA2 expression by activation of the KPNA2 promoter (25) . E2F activity is regulated by extracellular growth factors, including hepatocyte growth factor or basic fibroblast growth factor (26) . Therefore, KPNA2 expression might be regulated by cancer stromal cells via secretion of one or more growth factors. Nuclear KPNA2 expression was higher in the marginal regions of GC tissues associated with cancer stromal cells. Moreover, cancer cells in the marginal regions of the tumor reportedly acquire cancer stem cell features via hepatocyte growth factor stimulation. Hepatocyte growth factor is secreted by cancer stromal cells, including cancer-associated fibroblasts in colon cancer and esophageal cancer (27, 28) . From these observations, we suggest that KPNA2 expression in the marginal regions of primary GC and metastatic lymph nodes might be regulated by growth factors originating from cancer stromal cells.
In this study, it was important to develop a prognostic tool for GC patients to predict the risk of recurrence after curative resection. In a large-scale clinical study, it was reported that adjuvant chemotherapy for GC with lymph node metastasis is an effective treatment for recurrence prevention after curative operation (29) . Importantly, half of the patients with metastatic lymph nodes were completely cured by surgery alone, although these patients would normally receive adjuvant chemotherapy treatment. On the other hand, some patients have recurred in spite of receiving adjuvant chemotherapy. In this study, we found that high expression of nuclear KPNA2 in marginal regions of metastatic lymph nodes was predominantly correlated with poor prognosis. Hence, KPNA2 may be a marker capable of identifying patients with a high risk of recurrence and more reliably indicate postoperative adjuvant therapy.
In conclusion, the expression of nuclear KPNA2 correlated with GC progression. KPNA2 expression could be a useful prognostic marker for GC, especially for lymph node-positive GC patients. In addition, KPNA2 regulated GC cell proliferation and resistance to cisplatin in in vitro analysis. With respect to developing new molecular cancer therapies, KPNA2 might be a promising candidate for targeted therapy in GC. 
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